Search

everythinglearnresearchcommunity

for

Search:↓

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

JAK inhibitors are effective treatments for alopecia areata.

Finasteride significantly reduces the risk of prostate cancer.

Tofacitinib may help regrow hair in alopecia areata patients.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

DA-9401 can protect against finasteride-induced reproductive damage in rats.

Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

JAK inhibitors are effective for long-term management of alopecia areata.

A new treatment for hair loss shows promise with fewer side effects.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.